Skip to content
HowShorted

TransMedics Group, Inc. short interest in 2024

In 2024, TransMedics Group, Inc.'s disclosed short interest ran from 16.60% of shares outstanding on 12 Jan 2024 to 27.27% on 31 Dec 2024, a change of +10.67 percentage points. The year's high was 27.68% on 29 Nov 2024 and its low 15.07% on 15 Feb 2024, averaging 19.21% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.41 days on 31 Jan 2024. Full history: TransMedics Group, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TransMedics Group, Inc. in 2024

2024 in figures

Start of year
16.60% (12 Jan 2024)
End of year
27.27% (31 Dec 2024)
Change
+10.67 pp
High
27.68% (29 Nov 2024)
Low
15.07% (15 Feb 2024)
Average
19.21%
Highest days to cover
14.41 (31 Jan 2024)
SEC filings marked
8

Every report in 2024

TransMedics Group, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202416.60%9.51
31 Jan 202416.58%14.41
15 Feb 202415.07%13.14
29 Feb 202415.23%4.09results (8-K), 10-K filed
15 Mar 202416.53%8.55
28 Mar 202418.31%8.39
15 Apr 202419.33%6.82
30 Apr 202416.46%6.86results (8-K)
15 May 202416.10%3.9510-Q filed
31 May 202417.50%8.12
14 Jun 202418.16%8.86
28 Jun 202418.22%7.49
15 Jul 202417.83%10.35
31 Jul 202417.22%9.49results (8-K)
15 Aug 202418.18%5.5810-Q filed
30 Aug 202417.60%9.03
13 Sep 202416.48%5.29
30 Sep 202417.93%3.57
15 Oct 202419.19%7.55
31 Oct 202425.11%3.14results (8-K), 10-Q filed
15 Nov 202426.74%5.77
29 Nov 202427.68%5.37
13 Dec 202425.74%4.19
31 Dec 202427.27%7.00

See also: TransMedics Group, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.